B E Kitchell
Overview
Explore the profile of B E Kitchell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
356
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gustafson T, Kitchell B, Biller B
Vet Comp Oncol
. 2015 Apr;
15(1):174-183.
PMID: 25864514
Transitional cell carcinoma (TCC) is the most commonly diagnosed tumor of the canine urinary system. Hedgehog (HH) signaling represents one possible novel therapeutic target, based on its recently identified central...
2.
Batschinski K, Dervisis N, Kitchell B
Vet Comp Oncol
. 2012 Sep;
12(4):249-57.
PMID: 22985083
A retrospective study was performed to assess toxicity and response rate of ifosfamide salvage treatment for dogs diagnosed with metastatic osteosarcoma (OSA). Dogs diagnosed with OSA and previously treated with...
3.
Dank G, Rassnick K, Sokolovsky Y, Garrett L, Post G, Kitchell B, et al.
Vet Comp Oncol
. 2012 Jun;
12(1):78-84.
PMID: 22737988
Melanoma is the most common oral malignancy in dogs. This retrospective study evaluated adjuvant carboplatin chemotherapy (with or without radiation therapy) in 17 dogs with malignant oral melanoma following surgical...
4.
Smedley R, Spangler W, Esplin D, Kitchell B, Bergman P, Ho H, et al.
Vet Pathol
. 2011 Jan;
48(1):54-72.
PMID: 21266721
Many studies have evaluated various prognostic markers for canine melanocytic neoplasms either as primary or secondary goals; however, design, methodology, and statistical validation vary widely across these studies. The goal...
5.
FitzPatrick W, Dervisis N, Kitchell B
Vet Comp Oncol
. 2010 Nov;
8(4):273-82.
PMID: 21062409
Doxorubicin may cause a rare but serious cardiotoxicity. Dexrazoxane is a cardioprotectant drug used to reduce the risk of cardiotoxicity in human patients. In this study, 25 tumour-bearing dogs were...
6.
de Mello Souza C, Valli V, Selting K, Kiupel M, Kitchell B
J Vet Intern Med
. 2010 Aug;
24(5):1112-7.
PMID: 20707846
Background: Retinoids exert their effects by binding to retinoid receptors. Two types of retinoid receptors have been described: retinoic acid receptor (RAR) and retinoid X receptor (RXR), and their subtypes...
7.
Webster J, Dennis M, Dervisis N, Heller J, Bacon N, Bergman P, et al.
Vet Pathol
. 2010 Jul;
48(1):7-18.
PMID: 20664014
There is an increasing need for more accurate prognostic and predictive markers in veterinary oncology because of an increasing number of treatment options, the increased financial costs associated with treatment,...
8.
Harrison T, McKnight C, Sikarskie J, Kitchell B, Garner M, Raymond J, et al.
Vet Pathol
. 2010 Jul;
47(5):952-7.
PMID: 20610770
Malignant lymphoma has become an increasingly recognized problem in African lions (Panthera leo). Eleven African lions (9 male and 2 female) with clinical signs and gross and microscopic lesions of...
9.
10.
Martinez-Ruzafa I, Dominguez P, Dervisis N, Sarbu L, Newman R, Cadile C, et al.
J Vet Intern Med
. 2009 Mar;
23(3):570-7.
PMID: 19298611
Background: This study was performed to determine the toxicity of gemcitabine-carboplatin doublet therapy in cats with carcinomas. Hypothesis: Gemcitabine and carboplatin are safe in tumor-bearing cats. Animals: Twenty cats with...